Generic Name and Formulations:
Anidulafungin 50mg/vial, 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free; contains fructose and mannitol.
Indications for ERAXIS:
Candidemia. Esophageal candidiasis. Other Candida infections (intra-abdominal abscess, peritonitis).
Give by IV infusion; max rate 1.1mg/minute. Candidiasis, intra-abdominal abscess, peritonitis: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution.
≤16yrs: not established.
Glucan synthesis inhibitor (echinocandin).
Follow-up if hepatic dysfunction develops. Discontinue and treat appropriately if anaphylactic reactions occur. Pregnancy (Cat.B). Nursing mothers.
Hypokalemia, GI upset, pyrexia, insomnia, anemia, headache, dyspepsia; hepatic effects, infusion reactions, anaphylactic reactions.
Fecal, renal (minor).
- 50mg vials (Qty:14)
- appx. price $1297.00
- Recall of Two IV Antibiotics Announced
- Five Things ID Experts Want You to Know Before You Prescribe an Antibiotic
- What's Changed in Immunization Recommendations From CDC Advisory Committee
- IUD Approval Gives Women New Long-Acting Birth Control Option
- Vitamin D: Greater Risk Factor for Diabetes Than Weight?
- Pharmacologic Management of Obesity: Endocrine Society's New Guidelines
- Withdrawn Drug Found in Weight Loss Supplement
- Neulasta Delivery Kit Provides New Option for Patients
- Even More Tainted Sex Enhancement Pills Discovered in International Shipments
- Melanoma Treatment Under Review for Preventing, Delaying Recurrence